Se connecter Inscription gratuite

Last updated: 2 December 2020 at 9:48am EST

Curt Bradshaw Net Worth



Curt Bradshaw ARWR stock SEC Form 4 insiders trading

Curt has made over 1 trades of the Arrowhead Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 31,250 units of ARWR stock worth $2,158,125 on 19 November 2020.

The largest trade he's ever made was selling 31,250 units of Arrowhead Pharmaceuticals stock on 19 November 2020 worth over $2,158,125. On average, Curt trades about 15,625 units every 0 days since 2020.

You can see the complete history of Curt Bradshaw stock trades at the bottom of the page.





Curt Bradshaw biography

Dr. Curt W. Bradshaw Ph.D. serves as Chief Scientific Officer of the Company. serves as Chief Scientific Officer of the Company. serves as Chief Scientific Officer of the Company. Dr. Bradshaw was President, Chief Scientific Officer, and a member of the board of directors for Tollnine, a company he co-founded to develop novel antibody conjugates for immuno-oncology. From 2012 — 2019 he served as Chief Scientific Officer and a member of the board of directors of Solstice Biologics, where he managed and oversaw all company operations and research exploring novel siRNA technologies for the development of human therapeutics. Before Solstice, Dr. Bradshaw was Vice President of Research and Development and Chief Scientific Officer at Traversa Therapeutics. At Traversa, he had primary R&D oversight and was a key strategic contributor to internal technology development, business strategy, and oversaw research alliances with multiple major pharmaceutical collaborators. Prior to Traversa, Dr. Bradshaw spent 7 years at CovX Research, a cornerstone of the Pfizer, Inc. Bioinnovation and Biotherapeutics Center. Prior to CovX, he spent 4 years at Ligand Pharmaceuticals and was responsible for the chemical development of clinical-phase active pharmaceutical ingredients. Dr. Bradshaw started his career at Abbott Laboratories, where he spent 6 years as a Research Chemist, Senior Research Chemist, and Project Leader. He received a PhD. in Organic Chemistry from Texas A&M University.



What's Curt Bradshaw's mailing address?

Curt's mailing address filed with the SEC is C/O 700 TECHNOLOGY DRIVE, , PITTSBURGH, PA, 15219.

Insiders trading at Arrowhead Pharmaceuticals

Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone et Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.



What does Arrowhead Pharmaceuticals do?

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing



What does Arrowhead Pharmaceuticals's logo look like?

Arrowhead Pharmaceuticals Inc. logo

Complete history of Curt Bradshaw stock trades at Arrowhead Pharmaceuticals et NeuBase Therapeutics

Date
#
Société
 Initié
Trans.
Transaction
 Actions Prix par action Prix ​​total Actions après Source
19 Nov 2020 ARWR Arrowhead Pharmaceuticals Inc. Curt Bradshaw
Chief Scientific Officer
 Vente 31,250 $69.06 $2,158,125
19 Nov 2020
0 ↗


Arrowhead Pharmaceuticals executives and stock owners

Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: